Liu Sheng, Tang Wenting, Cao Jing, Shang Mei, Sun Hengchang, Gong Jiao, Hu Bo
Department of Laboratory Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen Cancer Center, Guangzhou, China.
Front Genet. 2022 Jun 8;13:904114. doi: 10.3389/fgene.2022.904114. eCollection 2022.
Hepatitis A virus cellular receptor (HAVCR1) is a type-1 integral membrane glycoprotein that plays a key role in immunity and renal regeneration and is abnormally expressed in various tumor types. Nonetheless, the function of HAVCR1 in pan-cancer remains unknown. In this study, we comprehensively analyzed the expression and promoter methylation level of HAVCR1 and assessed the immune cell infiltration, correlation between stromal and immune cell admixture, CD (Cluster of Differentiation) and HAVCR1 expression and prognostic value of HAVCR1 mRNA expression in Liver hepatocellular carcinoma (LIHC) and Pancreatic adenocarcinoma (PAAD). Our results showed that HAVCR1 was overexpressed while the promoter methylation of HAVCR1 was decreased in Liver hepatocellular carcinoma and Pancreatic adenocarcinoma. HAVCR1 was associated with increased infiltration of B cells, CD8 cells, macrophages, neutrophils and Dendritic cells in Liver hepatocellular carcinoma and Pancreatic adenocarcinoma. HAVCR1 expression was positively correlated with the immune, stromal and estimate scores of Pancreatic adenocarcinoma and the stromal and estimate scores of Liver hepatocellular carcinoma. Furthermore, HAVCR1 expression was correlated with other immune molecules such as HHLA2 (Human endogenous retrovirus-H long terminal repeat-associating protein 2), CD44 and TNFRSF4 (TNF Receptor Superfamily Member 4) in Liver hepatocellular carcinoma and Pancreatic adenocarcinoma. During Kaplan-Meier analysis, high HAVCR1 expression in Liver hepatocellular carcinoma and Pancreatic adenocarcinoma correlated with poor survival. A marginally significant -value ( = 0.051) was obtained when the relationship between HAVCR1 expression in Liver hepatocellular carcinoma and prognosis was analyzed, attributed to the small sample size. Overall, we provided compelling evidence that HAVCR1 could be a prognostic and diagnostic marker for Liver hepatocellular carcinoma and Pancreatic adenocarcinoma.
甲型肝炎病毒细胞受体（HAVCR1）是一种1型整合膜糖蛋白，在免疫和肾脏再生中起关键作用，且在多种肿瘤类型中异常表达。尽管如此，HAVCR1在泛癌中的功能仍不清楚。在本研究中，我们全面分析了HAVCR1的表达和启动子甲基化水平，并评估了免疫细胞浸润、基质与免疫细胞混合比例、分化簇（CD）与HAVCR1表达之间的相关性，以及HAVCR1 mRNA表达在肝细胞癌（LIHC）和胰腺腺癌（PAAD）中的预后价值。我们的结果表明，在肝细胞癌和胰腺腺癌中，HAVCR1表达上调，而其启动子甲基化水平降低。HAVCR1与肝细胞癌和胰腺腺癌中B细胞、CD8细胞、巨噬细胞、中性粒细胞和树突状细胞浸润增加有关。HAVCR1表达与胰腺腺癌的免疫、基质和估计评分以及肝细胞癌的基质和估计评分呈正相关。此外，在肝细胞癌和胰腺腺癌中，HAVCR1表达与其他免疫分子如HHLA2（人类内源性逆转录病毒-H长末端重复序列结合蛋白2）、CD44和TNFRSF4（肿瘤坏死因子受体超家族成员4）相关。在Kaplan-Meier分析中，肝细胞癌和胰腺腺癌中HAVCR1高表达与较差的生存率相关。在分析肝细胞癌中HAVCR1表达与预后的关系时，由于样本量小，获得了一个边缘显著的P值（P = 0.051）。总体而言，我们提供了有力证据表明HAVCR1可能是肝细胞癌和胰腺腺癌的预后和诊断标志物。
